Venrock Healthcare Capital Partners III L.P. 13D and 13G filings for Taysha Gene Therapies, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 5:51 pm Sale |
2024-09-30 | 13G | Taysha Gene Therapies, Inc. TSHA |
Venrock Healthcare Capital Partners III L.P. | 9,000,000 4.400% |
-1,412,872 (-13.57%) |
Filing |
| 2024-02-14 8:44 pm Sale |
2023-12-31 | 13G | Taysha Gene Therapies, Inc. TSHA |
Venrock Healthcare Capital Partners III L.P. | 10,412,872 5.600% |
-4,031,572 (-27.91%) |
Filing |
| 2023-08-28 4:16 pm Purchase |
2023-08-16 | 13G | Taysha Gene Therapies, Inc. TSHA |
Venrock Healthcare Capital Partners III L.P. | 14,444,444 7.700% |
14,444,444 (New Position) |
Filing |